JP-1302

alpha2C-adrenoceptor antagonist, may have therapeutic potential for treatment of neuropsychiatric disorders; structure in first source

Also Known As:

acridin-9-yl-(4-(4-methylpiperazin-1-yl)-phenyl)amine

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - JP-1302: 4
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Acridines: 325
      - JP-1302: 4

Experts

1.	Hayashi, Kohei: 1 article (03/2019)
2.	Miura, Takeshi: 1 article (03/2019)
3.	Nishinaka, Toru: 1 article (03/2019)
4.	Shimokawa, Takaomi: 1 article (03/2019)
5.	Takama, Masashi: 1 article (03/2019)
6.	Terada, Tomoyuki: 1 article (03/2019)
7.	Tsutsui, Hidenobu: 1 article (03/2019)
8.	Yamagata, Masayo: 1 article (03/2019)
9.	Yoneda, Kozo: 1 article (03/2019)
10.	Yukimura, Tokihito: 1 article (03/2019)

Related Diseases

1.	Reperfusion Injury 03/01/2019 - "The aim of the present study is to investigate the effects of post-treatment with JP-1302 on renal ischemia/reperfusion injury in rats. " 03/01/2019 - "We previously revealed that pre-treatment with yohimbine or JP-1302 attenuated renal ischemia/reperfusion injury by inhibition of α2C-adrenoceptor antagonist. "
2.	Schizophrenia (Dementia Praecox) 11/01/2022 - "Therefore, the current study evaluates the behavioral and neurochemical effects of JP-1302, a selective α2C-adrenoceptor antagonist, in a model of schizophrenia-like deficits induced by sub-chronic ketamine (KET) administration. " 11/01/2022 - "The α2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits."
3.	Acute Kidney Injury (Acute Renal Failure) 03/01/2019 - "Post-treatment with JP-1302 protects against renal ischemia/reperfusion-induced acute kidney injury in rats." 03/01/2019 - "In conclusion, these results suggest that post-treatment with JP-1302 protects on ischemia/reperfusion-induced acute kidney injury by suppressing cytokine upregulation via α2C-adrenoceptors."
4.	Hypokinesia (Bradykinesia) 04/24/2009 - "JP-1302 (0.1-1 mg/kg, s.c.) dose-dependently ameliorated haloperidol-induced bradykinesia in the pole-test and reversed the catalepsy time increased by haloperidol. " 04/24/2009 - "We examined the effects of JP-1302 (a selective alpha2C antagonist), BRL-44408 (a selective alpha2A antagonist) and yohimbine (a non-selective alpha2 antagonist) on haloperidol-induced bradykinesia and catalepsy in mice to elucidate the role of alpha2 adrenoceptor subtypes in modifying extrapyramidal motor disorders. "
5.	Mydriasis 02/01/2007 - "Unlike the alpha2-subtype non-selective antagonist atipamezole, JP-1302 was not able to antagonize alpha2-agonist-induced sedation (measured as inhibition of spontaneous locomotor activity), hypothermia, alpha2-agonist-induced mydriasis or inhibition of vas deferens contractions, effects that have been generally attributed to the alpha2A-adrenoceptor subtype. "

Related Drugs and Biologics

1.	Ketamine
2.	Yohimbine (Yocon)
3.	Cytokines
4.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
5.	Adrenergic Receptors (Adrenergic Receptor)
6.	Haloperidol (Haldol)
7.	BRL 44408
8.	atipamezole
9.	salicylhydroxamic acid (SHAM)